首页 > 最新文献

Uirusu最新文献

英文 中文
[Polio vaccines and biorisk management of polioviruses]. [脊髓灰质炎疫苗和脊髓灰质炎病毒的生物风险管理]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.31
Yuichi Someya, Hiroyuki Shimizu
Japan is the first country where inactivated polio vaccines derived from Sabin attenuated strains, which are used to manufacture oral polio vaccines, were introduced in routine immunization program. The Sabin-derived inactivated vaccine has been developed based on the fact that Sabin strains are less neurovirulent and manufactured at safer productionfacilities than wild polioviruses. It is also convincing that Sabin strains are more safely used for evaluating the efficacy of inactivated vaccines in rat immunogenicity tests. However, in the current situation where polioviruses are close to being eradicated, the facilities that manufacture vaccines and/or conduct quality control of them are needed to meet the biorisk management requirements established by WHO, which are based on the Polio Eradication & Endgame Strategic Plan 2013-2018. At present, type 2 polioviruses including Sabin 2 strain should be contained in the facilities which meet the WHO biorisk management requirements. The respective facilities are expected to give full consideration based on a careful risk assessment of viral transmission not only to personnel, but also to the environment and the community around the facilities, and the establishment of biorisk management will be needed. Thus, the facilities handling and storing infectious polioviruses must be certified as poliovirus-essential facilities following the WHO biorisk management requirements.
日本是第一个将Sabin减毒株衍生的灭活脊髓灰质炎疫苗(用于生产口服脊髓灰质炎疫苗)引入常规免疫规划的国家。Sabin衍生灭活疫苗的开发基于以下事实:与野生脊髓灰质炎病毒相比,Sabin毒株的神经毒性较小,生产设施也更安全。同样令人信服的是,在大鼠免疫原性试验中,Sabin菌株更安全地用于评估灭活疫苗的效力。然而,在目前脊髓灰质炎病毒即将被根除的情况下,需要生产疫苗和/或对疫苗进行质量控制的设施,以满足世卫组织根据《2013-2018年消灭脊髓灰质炎和终局战略计划》制定的生物风险管理要求。目前,应将包括Sabin 2株在内的2型脊髓灰质炎病毒控制在符合世卫组织生物风险管理要求的设施中。预计各设施将在仔细评估病毒传播给人员、环境和设施周围社区的风险的基础上,充分考虑病毒传播的风险,并建立生物风险管理机制。因此,处理和储存传染性脊髓灰质炎病毒的设施必须按照世卫组织生物风险管理要求被认证为脊髓灰质炎病毒必需设施。
{"title":"[Polio vaccines and biorisk management of polioviruses].","authors":"Yuichi Someya, Hiroyuki Shimizu","doi":"10.2222/jsv.68.31","DOIUrl":"https://doi.org/10.2222/jsv.68.31","url":null,"abstract":"Japan is the first country where inactivated polio vaccines derived from Sabin attenuated strains, which are used to manufacture oral polio vaccines, were introduced in routine immunization program. The Sabin-derived inactivated vaccine has been developed based on the fact that Sabin strains are less neurovirulent and manufactured at safer productionfacilities than wild polioviruses. It is also convincing that Sabin strains are more safely used for evaluating the efficacy of inactivated vaccines in rat immunogenicity tests. However, in the current situation where polioviruses are close to being eradicated, the facilities that manufacture vaccines and/or conduct quality control of them are needed to meet the biorisk management requirements established by WHO, which are based on the Polio Eradication & Endgame Strategic Plan 2013-2018. At present, type 2 polioviruses including Sabin 2 strain should be contained in the facilities which meet the WHO biorisk management requirements. The respective facilities are expected to give full consideration based on a careful risk assessment of viral transmission not only to personnel, but also to the environment and the community around the facilities, and the establishment of biorisk management will be needed. Thus, the facilities handling and storing infectious polioviruses must be certified as poliovirus-essential facilities following the WHO biorisk management requirements.","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"31-40"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Functional analysis of Host proteins involved in RNA virus replication]. [参与 RNA 病毒复制的宿主蛋白质功能分析]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.71
Seiya Yamayoshi

Since RNA virus genome encodes only a limited number of viral proteins, replication of RNA virus mostly relies on host cells. Elucidation of host proteins that play important roles in the virus replication cycles contributes not only to fundamental virology research but also to applied research such as development of antiviral drugs. We revealed that Ebola virus matrix protein VP40 utilized host COPII transport machinery for its intracellular transport to the plasma membrane. Second, we demonstrated that enterovirus A71 used Scavenger receptor class B member 2 (SCARB2) as a cellular receptor. Finally, we found that host protein CLUH played an important role in the subnuclear transport of influenza virus ribonucleoprotein (vRNP) complexes. Here, I would like to briefly introduce these findings.

由于 RNA 病毒基因组只编码数量有限的病毒蛋白,因此 RNA 病毒的复制主要依赖宿主细胞。阐明在病毒复制周期中发挥重要作用的宿主蛋白不仅有助于病毒学基础研究,也有助于开发抗病毒药物等应用研究。我们揭示了埃博拉病毒基质蛋白 VP40 利用宿主 COPII 转运机制在细胞内转运至质膜。其次,我们证明肠病毒 A71 利用清道夫受体 B 类成员 2(SCARB2)作为细胞受体。最后,我们发现宿主蛋白CLUH在流感病毒核糖核蛋白(vRNP)复合物的核下转运中发挥了重要作用。在此,我想简要介绍一下这些发现。
{"title":"[Functional analysis of Host proteins involved in RNA virus replication].","authors":"Seiya Yamayoshi","doi":"10.2222/jsv.68.71","DOIUrl":"10.2222/jsv.68.71","url":null,"abstract":"<p><p>Since RNA virus genome encodes only a limited number of viral proteins, replication of RNA virus mostly relies on host cells. Elucidation of host proteins that play important roles in the virus replication cycles contributes not only to fundamental virology research but also to applied research such as development of antiviral drugs. We revealed that Ebola virus matrix protein VP40 utilized host COPII transport machinery for its intracellular transport to the plasma membrane. Second, we demonstrated that enterovirus A71 used Scavenger receptor class B member 2 (SCARB2) as a cellular receptor. Finally, we found that host protein CLUH played an important role in the subnuclear transport of influenza virus ribonucleoprotein (vRNP) complexes. Here, I would like to briefly introduce these findings.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"71-78"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.71","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hepatic tropism of hepatitis C virus infection]. [丙型肝炎病毒感染的肝嗜性]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.63
Takasuke Fukuhara

Hepatitis C virus (HCV) infects over 170 million people worldwide and is a major cause of life-threatening liver diseases such as liver cirrhosis and hepatocellular carcinoma. In current research, we aimed to clarify the mechanism of hepatic tropism of HCV infection. Although non-hepatic cells could not permit replication of HCV RNA, exogenous expression of liver specific miRNA, miR-122 facilitated efficient replication of viral RNA through direct interaction with 5'UTR of viral genome, indicating that miR-122 is one of the key determinants for hepatic tropism of HCV infection. In spite of efficient replication of viral RNA, formation of infectious particles was not observed in non-hepatic cells exogenously expressing miR-122. We found that expression of apolipoprotein E (ApoE) facilitated the formation of infectious HCV particles in non-hepatic cells, indicating that not only miR-122 but also ApoE participate in tissue tropism of HCV infection. To understand the exact roles of miR-122 and apolipoproteins in hepatic tropism of HCV, we established miR-122 and ApoB/ApoE knockout (KO) Huh7 cells, respectively. Although slight increase of intracellular HCV RNA and infectious titers in the culture supernatants was observed, propagation of HCV was impaired in miR-122 KO Huh7 cells. After serial passages of HCV in miR-122 KO cells, we obtained an adaptive mutant that possessed G28A substitutions in the 5'UTR of the HCV genome and exhibited efficient translation and replication in both miR-122 KO Huh7 and non-hepatic cells without exogenous expression of miR-122. These results suggest that HCV mutants replicating in non-hepatic cells in an miR-122-independent manner participate in the induction of extrahepatic manifestations in chronic hepatitis C patients. Deficiency of both ApoB and ApoE strongly inhibited the formation of infectious HCV particles. Interestingly, expression not only of ApoE but also of ApoA or ApoC could rescue the production of infectious HCV particles in ApoB/ApoE KO cells, suggesting that exchangeable apolipoproteins redundantly participate in the formation of infectious HCV particles.

丙型肝炎病毒(HCV)感染了全世界超过1.7亿人,是肝硬化和肝细胞癌等危及生命的肝脏疾病的主要原因。在目前的研究中,我们旨在阐明HCV感染的肝向性机制。尽管非肝细胞不允许HCV RNA复制,但外源性表达肝脏特异性miRNA, miR-122通过与病毒基因组5'UTR的直接相互作用促进病毒RNA的有效复制,表明miR-122是HCV感染肝性倾向的关键决定因素之一。尽管病毒RNA的有效复制,在外源表达miR-122的非肝细胞中未观察到感染性颗粒的形成。我们发现载脂蛋白E (ApoE)的表达促进了非肝细胞中感染性HCV颗粒的形成,这表明miR-122和ApoE都参与了HCV感染的组织趋向性。为了了解miR-122和载脂蛋白在HCV肝向性中的确切作用,我们分别建立了miR-122和ApoB/ApoE敲除(KO) Huh7细胞。虽然在培养上清中观察到细胞内HCV RNA和感染滴度略有增加,但HCV在miR-122 KO Huh7细胞中的增殖受到损害。在miR-122 KO细胞中连续传代HCV后,我们获得了一种适应性突变体,该突变体在HCV基因组的5'UTR中具有G28A替换,并且在miR-122 KO Huh7和无外源miR-122表达的非肝细胞中均表现出高效的翻译和复制。这些结果表明,在非肝细胞中以mir -122不依赖的方式复制的HCV突变体参与了慢性丙型肝炎患者肝外表现的诱导。ApoB和ApoE的缺乏强烈抑制感染性HCV颗粒的形成。有趣的是,在ApoB/ApoE KO细胞中,不仅表达ApoE,也表达ApoA或ApoC可以挽救感染性HCV颗粒的产生,这表明可交换的载脂蛋白冗余参与了感染性HCV颗粒的形成。
{"title":"[Hepatic tropism of hepatitis C virus infection].","authors":"Takasuke Fukuhara","doi":"10.2222/jsv.68.63","DOIUrl":"https://doi.org/10.2222/jsv.68.63","url":null,"abstract":"<p><p>Hepatitis C virus (HCV) infects over 170 million people worldwide and is a major cause of life-threatening liver diseases such as liver cirrhosis and hepatocellular carcinoma. In current research, we aimed to clarify the mechanism of hepatic tropism of HCV infection. Although non-hepatic cells could not permit replication of HCV RNA, exogenous expression of liver specific miRNA, miR-122 facilitated efficient replication of viral RNA through direct interaction with 5'UTR of viral genome, indicating that miR-122 is one of the key determinants for hepatic tropism of HCV infection. In spite of efficient replication of viral RNA, formation of infectious particles was not observed in non-hepatic cells exogenously expressing miR-122. We found that expression of apolipoprotein E (ApoE) facilitated the formation of infectious HCV particles in non-hepatic cells, indicating that not only miR-122 but also ApoE participate in tissue tropism of HCV infection. To understand the exact roles of miR-122 and apolipoproteins in hepatic tropism of HCV, we established miR-122 and ApoB/ApoE knockout (KO) Huh7 cells, respectively. Although slight increase of intracellular HCV RNA and infectious titers in the culture supernatants was observed, propagation of HCV was impaired in miR-122 KO Huh7 cells. After serial passages of HCV in miR-122 KO cells, we obtained an adaptive mutant that possessed G28A substitutions in the 5'UTR of the HCV genome and exhibited efficient translation and replication in both miR-122 KO Huh7 and non-hepatic cells without exogenous expression of miR-122. These results suggest that HCV mutants replicating in non-hepatic cells in an miR-122-independent manner participate in the induction of extrahepatic manifestations in chronic hepatitis C patients. Deficiency of both ApoB and ApoE strongly inhibited the formation of infectious HCV particles. Interestingly, expression not only of ApoE but also of ApoA or ApoC could rescue the production of infectious HCV particles in ApoB/ApoE KO cells, suggesting that exchangeable apolipoproteins redundantly participate in the formation of infectious HCV particles.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"63-70"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.63","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Virus resistance genes in plants]. [植物中的病毒抗性基因]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.13
Kazuhiro Ishibashi, Masayuki Ishikawa

Plants defend themselves from virus infection by RNA silencing and resistance (R) gene-mediated mechanisms. Many dominant R genes encode nucleotide-binding site and leucine-rich repeat (NB-LRR)-containing proteins. NB-LRR proteins are also encoded by R genes against bacteria or fungi, suggesting a similar mechanism underlies defense systems to diverse pathogens. In contrast, several non-NB-LRR-type R genes have recently been cloned, each of which differs from others in sequences and functions. In this review, we introduce a diversity of R gene-mediated plant defense systems against viruses. Tm-1, JAX1, and Scmv1, resistance genes against tomato mosaic virus, potexviruses, and sugarcane mosaic virus, respectively, inhibit virus multiplication at a single cell level. The RTM1, RTM2, RTM3 genes of Arabidopsis thaliana inhibit systemic transport of potyviruses through the phloem. STV11 of rice against rice stripe virus and Ty-1 and Ty-3 genes of tomato against tomato yellow leaf curl virus allow low level virus multiplication and confer tolerance. The wide diversity of plant defense systems against viruses implies their recent emergence. We suggest that plants evolved new defense systems to counter infection by viruses that had overcome pre-existing defense systems (RNA silencing and NB-LRR-type R gene-mediated systems).

植物通过RNA沉默和抗性(R)基因介导的机制保护自己免受病毒感染。许多显性R基因编码核苷酸结合位点和富含亮氨酸重复序列(NB-LRR)的蛋白。NB-LRR蛋白也由R基因编码,用于对抗细菌或真菌,这表明针对各种病原体的防御系统也存在类似的机制。相比之下,最近已经克隆了几个非nb - lrr型R基因,每个基因在序列和功能上都与其他基因不同。本文综述了R基因介导的植物抗病毒防御系统的多样性。Tm-1、JAX1和Scmv1分别是番茄花叶病毒、马铃薯病毒和甘蔗花叶病毒的抗性基因,它们在单细胞水平上抑制病毒的增殖。拟南芥的RTM1, RTM2, RTM3基因抑制多病毒通过韧皮部的全身运输。水稻抗水稻条纹病毒的STV11基因和番茄抗番茄黄卷叶病毒的Ty-1和Ty-3基因允许病毒低水平增殖并赋予耐受性。植物防御病毒系统的广泛多样性意味着它们是最近才出现的。我们认为植物进化出了新的防御系统来对抗病毒感染,这些防御系统已经克服了原有的防御系统(RNA沉默和nb - lrr型R基因介导系统)。
{"title":"[Virus resistance genes in plants].","authors":"Kazuhiro Ishibashi,&nbsp;Masayuki Ishikawa","doi":"10.2222/jsv.68.13","DOIUrl":"https://doi.org/10.2222/jsv.68.13","url":null,"abstract":"<p><p>Plants defend themselves from virus infection by RNA silencing and resistance (R) gene-mediated mechanisms. Many dominant R genes encode nucleotide-binding site and leucine-rich repeat (NB-LRR)-containing proteins. NB-LRR proteins are also encoded by R genes against bacteria or fungi, suggesting a similar mechanism underlies defense systems to diverse pathogens. In contrast, several non-NB-LRR-type R genes have recently been cloned, each of which differs from others in sequences and functions. In this review, we introduce a diversity of R gene-mediated plant defense systems against viruses. Tm-1, JAX1, and Scmv1, resistance genes against tomato mosaic virus, potexviruses, and sugarcane mosaic virus, respectively, inhibit virus multiplication at a single cell level. The RTM1, RTM2, RTM3 genes of Arabidopsis thaliana inhibit systemic transport of potyviruses through the phloem. STV11 of rice against rice stripe virus and Ty-1 and Ty-3 genes of tomato against tomato yellow leaf curl virus allow low level virus multiplication and confer tolerance. The wide diversity of plant defense systems against viruses implies their recent emergence. We suggest that plants evolved new defense systems to counter infection by viruses that had overcome pre-existing defense systems (RNA silencing and NB-LRR-type R gene-mediated systems).</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"13-20"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Arenavirus research and antiviral candidate]. [沙粒病毒研究和抗病毒候选药物]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.51
Hideki Tani, Urata Shuzo

Arenavirus is a genetic term for viruses belonging to the family Arenaviridae and is presented from lymphocytic choriomeningitis virus (LCMV), which shows almost no pathogenicity to humans, to Lassa virus, Junin virus, Machupo virus, Chapare virus, Lujo virus, Sabia virus, and Guanarito virus, which shows high pathogenicity to humans. These viruses except for LCMV are risk group 4 pathogens specified by World Health Organization. Based on this designation, it is designated as Class I pathogens in Japan. Although there have been no reports excluding one imported case of the Lassa fever patient, it is not surprising whenever imported cases occur in our country. Considering the disease severity and mortality rate, it is an urgent matter to develop vaccines and therapeutic drugs in endemic areas, and maintenances of these are also important in countries other than endemic areas. However, basic research on highly pathogenic arenavirus infections and development of therapeutic drugs are not easily progressed, because handling in highly safe research facilities is indispensable. In this article, we will outline the current knowledge from the recent basic research on arenavirus to the development situation of antivirals against arenaviruses.

沙粒病毒是沙粒病毒科病毒的一个遗传术语,从对人类几乎没有致病性的淋巴细胞性脉络丛脑膜炎病毒(LCMV)到对人类具有高致病性的拉沙病毒、朱宁病毒、马丘波病毒、查帕雷病毒、卢霍病毒、萨比亚病毒和瓜纳里托病毒。除LCMV外,这些病毒是世界卫生组织指定的第4类危险病原体。基于这个名称,它在日本被指定为I类病原体。虽然没有排除一例输入性拉沙热病例的报告,但每当我国出现输入性病例时,这并不奇怪。考虑到疾病的严重程度和死亡率,在流行地区开发疫苗和治疗药物是一件紧迫的事情,在流行地区以外的国家维持这些药物也很重要。然而,高致病性沙粒病毒感染的基础研究和治疗药物的开发并不容易取得进展,因为必须在高度安全的研究设施中进行处理。本文将从近年来沙粒病毒的基础研究到沙粒病毒抗病毒药物的发展现状进行综述。
{"title":"[Arenavirus research and antiviral candidate].","authors":"Hideki Tani,&nbsp;Urata Shuzo","doi":"10.2222/jsv.68.51","DOIUrl":"https://doi.org/10.2222/jsv.68.51","url":null,"abstract":"<p><p>Arenavirus is a genetic term for viruses belonging to the family Arenaviridae and is presented from lymphocytic choriomeningitis virus (LCMV), which shows almost no pathogenicity to humans, to Lassa virus, Junin virus, Machupo virus, Chapare virus, Lujo virus, Sabia virus, and Guanarito virus, which shows high pathogenicity to humans. These viruses except for LCMV are risk group 4 pathogens specified by World Health Organization. Based on this designation, it is designated as Class I pathogens in Japan. Although there have been no reports excluding one imported case of the Lassa fever patient, it is not surprising whenever imported cases occur in our country. Considering the disease severity and mortality rate, it is an urgent matter to develop vaccines and therapeutic drugs in endemic areas, and maintenances of these are also important in countries other than endemic areas. However, basic research on highly pathogenic arenavirus infections and development of therapeutic drugs are not easily progressed, because handling in highly safe research facilities is indispensable. In this article, we will outline the current knowledge from the recent basic research on arenavirus to the development situation of antivirals against arenaviruses.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"51-62"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[The Recent Epidemic Spread of Zika Virus Disease]. [最近寨卡病毒病的流行传播]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.1
Chang-Kweng Lim

Zika virus (ZIKV) is one of the members of the Spondweni serocomplex within the genus Flavivirus of the family Flaviviridae. The virus was first isolated from a serum specimen from a sentinel non-human primate in the Zika forest of Uganda in 1947. ZIKV is transmitted by Aedes aegypti and A. albopictus in an urban cycle and maintained in a sylvatic cycle between Aedes mosquitoes and monkeys in Africa and Asia. Initially, the virus was thought to cause only mild and nonspecific clinical symptoms in humans. However, ZIKV became a serious public health concern in recent years due to an association with congenital malformation known as microcephaly in newborns as well as Guillain-Barré syndrome and other neurologic disorders in adults. The severe nature of complications of ZIKV infection have led to an urgent need for a safe and effective vaccine worldwide including Japan. The first large outbreak of disease caused by ZIKV infection was reported from the island of Yap, Micronesia in 2007. It was followed by outbreaks in French Polynesia, Cook Islands, Ester Island, and New Caledonia in 2013 and 2014. In 2015, ZIKV outbreak was reported in Brazil and has spread across the Latin America, and the Caribbean. The exact prevalence of ZIKV infection has not been reported because of the absence of a standardized protocol for differential diagnosis and its clinical resemblance to dengue virus and other flavivirus infections. In Japan, the first human case of ZIK fever, who developed illness soon after returning from French Polynesia, was reported in 2013, and until 2017, 20 imported cases were documented. Currently, research on ZIKV has progressed remarkably thus this article aims to review recent progress in virology, epidemiology, and pathology of ZIKV infection.

寨卡病毒(ZIKV)是黄病毒科黄病毒属Spondweni血清复合体的成员之一。1947年,这种病毒首次从乌干达寨卡森林中一种非人类灵长类动物的血清样本中分离出来。寨卡病毒由埃及伊蚊和白纹伊蚊以城市循环传播,并在非洲和亚洲的伊蚊和猴子之间以森林循环传播。最初,人们认为这种病毒只会在人类中引起轻微和非特异性的临床症状。然而,由于寨卡病毒与新生儿小头畸形以及格林-巴-罗综合征和其他成人神经系统疾病有关,近年来寨卡病毒已成为一个严重的公共卫生问题。寨卡病毒感染并发症的严重性质导致包括日本在内的全世界迫切需要一种安全有效的疫苗。2007年密克罗尼西亚雅浦岛报告了由寨卡病毒感染引起的第一次大规模疾病暴发。随后,2013年和2014年在法属波利尼西亚、库克群岛、伊斯特岛和新喀里多尼亚爆发疫情。2015年,巴西报告了寨卡病毒疫情,并已蔓延到整个拉丁美洲和加勒比地区。由于缺乏鉴别诊断的标准化方案以及其与登革热病毒和其他黄病毒感染的临床相似性,没有报告寨卡病毒感染的确切流行率。在日本,2013年报告了从法属波利尼西亚返回后不久出现的第一例人间寨卡热病例,到2017年,记录了20例输入性病例。目前,对寨卡病毒的研究取得了显著进展,本文就寨卡病毒的病毒学、流行病学和病理学方面的最新进展进行综述。
{"title":"[The Recent Epidemic Spread of Zika Virus Disease].","authors":"Chang-Kweng Lim","doi":"10.2222/jsv.68.1","DOIUrl":"https://doi.org/10.2222/jsv.68.1","url":null,"abstract":"<p><p>Zika virus (ZIKV) is one of the members of the Spondweni serocomplex within the genus Flavivirus of the family Flaviviridae. The virus was first isolated from a serum specimen from a sentinel non-human primate in the Zika forest of Uganda in 1947. ZIKV is transmitted by Aedes aegypti and A. albopictus in an urban cycle and maintained in a sylvatic cycle between Aedes mosquitoes and monkeys in Africa and Asia. Initially, the virus was thought to cause only mild and nonspecific clinical symptoms in humans. However, ZIKV became a serious public health concern in recent years due to an association with congenital malformation known as microcephaly in newborns as well as Guillain-Barré syndrome and other neurologic disorders in adults. The severe nature of complications of ZIKV infection have led to an urgent need for a safe and effective vaccine worldwide including Japan. The first large outbreak of disease caused by ZIKV infection was reported from the island of Yap, Micronesia in 2007. It was followed by outbreaks in French Polynesia, Cook Islands, Ester Island, and New Caledonia in 2013 and 2014. In 2015, ZIKV outbreak was reported in Brazil and has spread across the Latin America, and the Caribbean. The exact prevalence of ZIKV infection has not been reported because of the absence of a standardized protocol for differential diagnosis and its clinical resemblance to dengue virus and other flavivirus infections. In Japan, the first human case of ZIK fever, who developed illness soon after returning from French Polynesia, was reported in 2013, and until 2017, 20 imported cases were documented. Currently, research on ZIKV has progressed remarkably thus this article aims to review recent progress in virology, epidemiology, and pathology of ZIKV infection.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Herpes Zoster Vaccine]. 带状疱疹疫苗。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.21
Daisuke Watanabe

Herpes zoster, or shingles, results from the reactivation of latent varicella- zoster virus (VZV) in the dorsal-root or cranial-nerve ganglia, usually decades after primary infection. Herpes zoster is characterized by a vesicular rash with a unilateral and dermatomal distribution and is almost always accompanied by pain. Herpes zoster is not only skin disease, but also sometimes affects other organs, including central nerve system, eye, and facial nerve. The most common complications, such as postherpetic neuralgia (PHN), are more frequent, severe and impair patients' quality of life. For more than 10 years, in US, EU, and Australia, a live-attenuated vaccine against herpes zoster (Zostavax) containing the Oka VZV strain is licensed for use in adults who are 50 years of age or older. In Japan, a live attenuated varicella vaccine is also licensed for preventing herpes zoster in 2016. Two large randomized multinational efficacy trials (ZOE-50 and ZOE-70) showed that the novel herpes zoster subunit vaccine (shinglix) candidate containing varicella-zoster virus glycoprotein E (gE) and the AS01B adjuvant system reduced the risk of herpes zoster and PHN by more than 90%. This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines.

带状疱疹,或带状疱疹,由潜伏的水痘-带状疱疹病毒(VZV)在背根或颅神经节重新激活引起,通常在初次感染后几十年。带状疱疹的特征是单侧和皮肤分布的水疱疹,几乎总是伴有疼痛。带状疱疹不仅是一种皮肤病,有时还会影响其他器官,包括中枢神经系统、眼睛和面神经。最常见的并发症,如带状疱疹后神经痛(PHN),更频繁,严重,损害患者的生活质量。10多年来,在美国、欧盟和澳大利亚,一种含有Oka VZV毒株的带状疱疹减毒活疫苗(Zostavax)获准用于50岁或以上的成年人。在日本,一种减毒水痘活疫苗也于2016年获得了预防带状疱疹的许可。两项大型随机多国疗效试验(ZOE-50和ZOE-70)显示,含有水痘-带状疱疹病毒糖蛋白E (gE)和AS01B佐剂系统的新型带状疱疹亚单位疫苗(shinglix)候选疫苗可将带状疱疹和PHN的风险降低90%以上。本文综述了带状疱疹的流行病学、病理生理和并发症,并就带状疱疹减毒活疫苗和新型重组带状疱疹疫苗的疗效和存在的问题进行了综述。
{"title":"[Herpes Zoster Vaccine].","authors":"Daisuke Watanabe","doi":"10.2222/jsv.68.21","DOIUrl":"https://doi.org/10.2222/jsv.68.21","url":null,"abstract":"<p><p>Herpes zoster, or shingles, results from the reactivation of latent varicella- zoster virus (VZV) in the dorsal-root or cranial-nerve ganglia, usually decades after primary infection. Herpes zoster is characterized by a vesicular rash with a unilateral and dermatomal distribution and is almost always accompanied by pain. Herpes zoster is not only skin disease, but also sometimes affects other organs, including central nerve system, eye, and facial nerve. The most common complications, such as postherpetic neuralgia (PHN), are more frequent, severe and impair patients' quality of life. For more than 10 years, in US, EU, and Australia, a live-attenuated vaccine against herpes zoster (Zostavax) containing the Oka VZV strain is licensed for use in adults who are 50 years of age or older. In Japan, a live attenuated varicella vaccine is also licensed for preventing herpes zoster in 2016. Two large randomized multinational efficacy trials (ZOE-50 and ZOE-70) showed that the novel herpes zoster subunit vaccine (shinglix) candidate containing varicella-zoster virus glycoprotein E (gE) and the AS01B adjuvant system reduced the risk of herpes zoster and PHN by more than 90%. This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"21-30"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Pathogenic mechanisms of Tick-borne Flaviviruses]. [蜱传黄病毒的致病机制]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.78
Kentaro Yoshii

Many tick-borne flaviviruses causes fatal encephalitis in humans and animals with severe sequelae. However, it remains unclear how viral replication and pathogenicity contribute to the neurologic manifestations. In this paper, I summarized the specific replication mechanism of tick-borne flaviviruses in neurons and their effect on the pathogenicity of neurological disease. Our findings of the unique virus-host interaction in central nerve system will improve further understanding of the molecular mechanisms of viral replication and the pathogenicity of neurotropic viruses.

许多蜱传黄病毒在人和动物中引起致命的脑炎,并伴有严重的后遗症。然而,目前尚不清楚病毒复制和致病性如何导致神经系统表现。本文综述了蜱传黄病毒在神经细胞内的具体复制机制及其在神经系统疾病致病性中的作用。我们在中枢神经系统中独特的病毒-宿主相互作用的发现将有助于进一步了解病毒复制的分子机制和嗜神经病毒的致病性。
{"title":"[Pathogenic mechanisms of Tick-borne Flaviviruses].","authors":"Kentaro Yoshii","doi":"10.2222/jsv.68.78","DOIUrl":"https://doi.org/10.2222/jsv.68.78","url":null,"abstract":"<p><p>Many tick-borne flaviviruses causes fatal encephalitis in humans and animals with severe sequelae. However, it remains unclear how viral replication and pathogenicity contribute to the neurologic manifestations. In this paper, I summarized the specific replication mechanism of tick-borne flaviviruses in neurons and their effect on the pathogenicity of neurological disease. Our findings of the unique virus-host interaction in central nerve system will improve further understanding of the molecular mechanisms of viral replication and the pathogenicity of neurotropic viruses.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"78-88"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.78","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37257384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
[Recent topics in the research field of severe fever with thrombocytopenia syndrome (SFTS)]. [发热伴血小板减少综合征(SFTS)研究领域的最新课题]。
Pub Date : 2018-01-01 DOI: 10.2222/jsv.68.41
Masayuki Saijo

Seven years have passed since the discovery of a novel infectious disease, severe fever with thrombocytopenia syndrome (SFTS) caused by a novel Phlebovirus, SFTS virus (SFTSV), in PR China. It was also confirmed that SFTS was endemic to Japan through an identification of a woman, who died of SFTSV infection in Yamaguchi prefecture in late 2012. Approximately 6 years have passed since the discovery of SFTS-endemicity in Japan. At present, SFTS is endemic to PR China, South Korea and western Japan. SFTSV is maintained between several species of ticks such as Haemaphysalis longicornis and wild and domestic animals in nature. Therefore, we cannot escape from the risk of being infected with SFTSV. Based on the similarity in the characteristics of the clinical symptoms including the high case fatality rate, mode of infection to humans, pathology and virology between SFTS and Crimean-Congo hemorrhagic fever (CCHF), SFTS should be classified as viral hemorrhagic fever. Although the time from the discovery of SFTS is still short, there have been many scientific reports on the epidemiological, clinical, and/or pathological, and virological studies on SFTS. Favipiravir was reported to show an efficacy in the prevention and treatment of SFTSV infections in an animal model. A clinical study to evaluate the efficacy of favipiravir in the treatment of SFTS patients has been initiated in Japan. Specific and effective treatment with antiviral drugs for and preventive measures of SFTS with vaccination shoued be developed through scientific, clinical, and basic research.

自中国发现由一种新型静脉病毒SFTS病毒(SFTSV)引起的重症发热伴血小板减少综合征(SFTS)以来,已经过去了7年。通过对2012年底在山口县死于SFTSV感染的一名妇女的鉴定,还确认了SFTS在日本的地方性流行。自日本发现sfts地方病以来,大约已经过去了6年。目前,SFTS在中华人民共和国、韩国和日本西部流行。SFTSV在几种蜱(如长角血蜱)与自然界的野生动物和家畜之间维持。因此,我们无法逃避感染SFTSV的风险。基于SFTS与克里米亚-刚果出血热(CCHF)在高病死率、人感染方式、病理和病毒学等临床症状特征上的相似性,SFTS应归类为病毒性出血热。虽然从发现SFTS的时间还很短,但已经有许多关于SFTS的流行病学、临床和/或病理和病毒学研究的科学报道。据报道,Favipiravir在动物模型中显示出预防和治疗SFTSV感染的功效。一项评估favipiravir治疗SFTS患者疗效的临床研究已在日本启动。通过科学研究、临床研究和基础研究,制定有效的抗病毒药物治疗方案和疫苗接种预防措施。
{"title":"[Recent topics in the research field of severe fever with thrombocytopenia syndrome (SFTS)].","authors":"Masayuki Saijo","doi":"10.2222/jsv.68.41","DOIUrl":"https://doi.org/10.2222/jsv.68.41","url":null,"abstract":"<p><p>Seven years have passed since the discovery of a novel infectious disease, severe fever with thrombocytopenia syndrome (SFTS) caused by a novel Phlebovirus, SFTS virus (SFTSV), in PR China. It was also confirmed that SFTS was endemic to Japan through an identification of a woman, who died of SFTSV infection in Yamaguchi prefecture in late 2012. Approximately 6 years have passed since the discovery of SFTS-endemicity in Japan. At present, SFTS is endemic to PR China, South Korea and western Japan. SFTSV is maintained between several species of ticks such as Haemaphysalis longicornis and wild and domestic animals in nature. Therefore, we cannot escape from the risk of being infected with SFTSV. Based on the similarity in the characteristics of the clinical symptoms including the high case fatality rate, mode of infection to humans, pathology and virology between SFTS and Crimean-Congo hemorrhagic fever (CCHF), SFTS should be classified as viral hemorrhagic fever. Although the time from the discovery of SFTS is still short, there have been many scientific reports on the epidemiological, clinical, and/or pathological, and virological studies on SFTS. Favipiravir was reported to show an efficacy in the prevention and treatment of SFTSV infections in an animal model. A clinical study to evaluate the efficacy of favipiravir in the treatment of SFTS patients has been initiated in Japan. Specific and effective treatment with antiviral drugs for and preventive measures of SFTS with vaccination shoued be developed through scientific, clinical, and basic research.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"68 1","pages":"41-50"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.68.41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37254980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[How polyomavirus crosses the endoplasmic reticulum membrane to gain entry into the cytosol]. [多瘤病毒如何穿过内质网膜进入细胞质溶胶]。
Pub Date : 2017-01-01 DOI: 10.2222/jsv.67.121
Takamasa Inoue

Polyomavirus (Py) is a non-enveloped, double stranded DNA virus that causes a myriad of devastating human diseases for immunocompromised individuals. To cause infection, Py binds to its receptors on the plasma membrane, is endocytosed, and sorts to the endoplasmic reticulum (ER). From here, Py penetrates the ER membrane to reach the cytosol. Ensuing nuclear entry enables the virus to cause infection. How Py penetrates the ER membrane to access the cytosol is a decisive infection step that is enigmatic. In this review, I highlight the mechanisms by which host cell functions facilitate Py translocation across the ER membrane into the cytosol.

多瘤病毒(Py)是一种非包膜双链DNA病毒,对免疫功能低下的个体造成无数毁灭性的人类疾病。为了引起感染,Py与质膜上的受体结合,被内吞,并转运到内质网(ER)。从这里,Py穿过内质网膜到达细胞质溶胶。随后进入细胞核使病毒引起感染。Py如何穿透内质网膜进入细胞质是一个谜一样的决定性感染步骤。在这篇综述中,我强调了宿主细胞功能促进Py通过内质网膜转运到细胞质的机制。
{"title":"[How polyomavirus crosses the endoplasmic reticulum membrane to gain entry into the cytosol].","authors":"Takamasa Inoue","doi":"10.2222/jsv.67.121","DOIUrl":"https://doi.org/10.2222/jsv.67.121","url":null,"abstract":"<p><p>Polyomavirus (Py) is a non-enveloped, double stranded DNA virus that causes a myriad of devastating human diseases for immunocompromised individuals. To cause infection, Py binds to its receptors on the plasma membrane, is endocytosed, and sorts to the endoplasmic reticulum (ER). From here, Py penetrates the ER membrane to reach the cytosol. Ensuing nuclear entry enables the virus to cause infection. How Py penetrates the ER membrane to access the cytosol is a decisive infection step that is enigmatic. In this review, I highlight the mechanisms by which host cell functions facilitate Py translocation across the ER membrane into the cytosol.</p>","PeriodicalId":75275,"journal":{"name":"Uirusu","volume":"67 2","pages":"121-132"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2222/jsv.67.121","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36625429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Uirusu
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1